Latest News and Press Releases

Media ReleaseCOPENHAGEN, Denmark; December 6, 2025 New two- and three-year EPCORE® NHL-2 follow-up data evaluating epcoritamab in combination with standard of care regimens demonstrate remission in...

Objective response rate (ORR) of 83% including two complete responses in CLL patients in Phase 1a study with median progression free survival (PFS) of 22.1 months across all doses tested Emerging...

-- Bezuclastinib achieves clear clinical benefit across all symptom domains including significant improvements on 11 individual symptoms plus the most severe symptom at baseline -- ...

Austin, Dec. 06, 2025 (GLOBE NEWSWIRE) -- The In-Memory Database Market size was valued at USD 17.53 Billion in 2025E and is projected to reach USD 59.58 Billion by 2033, growing at a CAGR of 16.54%...

Follow-up data from CARTITUDE-4 show at least 80 percent of as-treated standard-risk patients remained progression- and treatment-free following a single infusion as early as second line1 Data...

The complaint alleges Blue Owl hid BDC-redemption pressure, liquidity issues, and likely redemption limits, making its positive statements misleading.

The complaint alleges Cepton hid a higher bid, failed to evaluate or disclose it, depriving shareholders of a fair choice and making statements misleading.

Technological advancements in peptide synthesis, expanding R&D pipelines, and strong U.S. market leadership accelerate sector growth at a CAGR of 7.51%.

The complaint alleges Marex sold OTC instruments to itself, had major financial inconsistencies, issued unreliable financials, and misled investors.

The complaint alleges defendants overstated Efzofitimod’s efficacy, hid steroid-taper issues, and inflated aTyr’s stock through these misstatements.